Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

disease.

The Company believes that microplasmin may represent a major advance in this area, as detaching the vitreous from the retina has been associated with greatly reducing the growth of new blood vessels (neovascularization) on the retina, which plays a fundamental role in the loss of vision in many diabetic patients.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment in MIVI II DME. This initial study is an important first step in evaluating microplasmin's effect in the diabetic retinopathy population in general. Microplasmin could represent an important treatment option for this patient population, given numerous studies from various groups showing the clinical benefits of vitreous detachment in diabetic retinopathy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at '/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ... for the fourth quarter of 2013 on Monday, February ... scheduled for release after the close of trading. ... will hold a conference call to discuss the operating ... twelve months ended December 31, 2013 on February 3, ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... maintain the anatomical reduction (spacing) of the scaphoid and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, ... development of disease modifying therapeutics for Alzheimer,s disease ... relocation of its corporate headquarters to ... 2014 and expanded lease agreement for additional laboratory ... Oligomerix, which is focused on the development of ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey ... is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the ... , , ... , , ...
... Calif. , July 22 SRI International and the ... Collaborative (the Multidisciplinary Initiative for Surgical Technology Research Advanced Laboratory), in ... $1M grant by the Food and Drug Administration (FDA) ... care. , , ...
Cached Medicine Technology:Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 2Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... marketer and,distributor of pharmaceutical, medicinal and diagnostic products ... conference call at 5:00 p.m. Eastern,Time on May ... financial results., Joining Mr. Yan-qing Liu, Chairman, ...
... baby was bottle-fed, researchers noted , , TUESDAY, May 13 ... than one year reduce their risk of rheumatoid arthritis ... , The researchers also found that having children but ... , Taking oral contraceptives also failed to reduce the ...
... -- Promising results from a team of NewYork-Presbyterian Hospital/Weill ... both safe and effective at slowing the progression of ... a rare, genetic, degenerative neurological disorder that usually becomes ... 12. , The clinical trial found that the ...
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... a,renegade internet radio broadcaster and production company promoter, but ... particularly those with,disabilities - not exactly what you,d expect ... with the Hard Rock Cafe at Station Square,Lawless and ... planned,Pittsburgh,s first annual Rock for Autism on June 11, ...
... A complete review of trends in,weight loss research ... to weight loss, according to Edward Zbella, M.D.,Medical ... proven,weight management strategies in combination with a personal, ... success., NBC,s hit show The Biggest Loser ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2Health News:Rockin' Out for Autism in Pittsburgh 2Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Medicine Products: